findmyKOL

Amy Rothberg, MD

Basic profile

University of Michigan

ORCIDNPI
RegionAnn Arbor, MI · MidwestSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Last active 2024findmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH funding2020–2024Why? →

Amy Rothberg is an Endocrinology/Metabolic physician affiliated with University of Michigan. OpenAlex indexes 94 publications with 2,383 citations (h-index 25); ClinicalTrials.gov lists 2 registered studies matched to this name.

Overview

Scholarship

indexed output and impact (OpenAlex)
94publications

Distinct works indexed by OpenAlex, matched via ORCID.

2,383citations

Total citations across indexed works.

25h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
2clinical trials

Investigator role on registered studies.

View trials
2companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2020–2024

Federally funded research awards.

View funding

Clinical trials

Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.

Industry payments

2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

2 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    75.3%
    GLP-1 receptor agonist38%
    Ozempic42%Trulicity32%Mounjaro26%
    Part D<11 patients
    Insulin Analog22.7%
    Lantus Solostar65%Novolog Flexpen35%
    Part D<11 patients

    + 1 more class in this area

  • Cardiovascular

    16%
    Statin8.7%
    Atorvastatin Calcium100%
    Part D<11 patients
    Calcium channel blocker7.3%
    Amlodipine Besylate100%
    Part D<11 patients
  • Nervous system

    8.7%
    Aminoketone8.7%
    Bupropion Xl100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 20202024 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”